3-FPM: Difference between revisions

Line 14:

==Pharmacology==

3-FPM is a sympathomimetic drug which has classical [[stimulant]] effects when consumed. Its mechanism of action appears to function by acting as a [[releasing agent]] for [[dopamine]]~~, [[serotonin]],~~ and [[norepinephrine]], increasing their concentrations in the synaptic clefts of neurons in the brain. This accumulation of [[neurotransmitters]] results in the experience of [[physical euphoria|euphoric]] and [[stimulation|stimulating]] effects~~. Notably, it has a higher affinity for all three [[monoamine]] transporters when compared to [[methylphenidate]]~~. Its parent compound, phenmetrazine, was previously marketed as an [[appetite suppressant]] in the 60s and 70s but has since been withdrawn from the market due to concerns of abuse and addiction.

3-FPM is a sympathomimetic drug which has classical [[stimulant]] effects when consumed. Its mechanism of action appears to function by acting as a [[releasing agent]] for [[dopamine]] and [[norepinephrine]], increasing their concentrations in the synaptic clefts of neurons in the brain. This accumulation of [[neurotransmitters]] results in the experience of [[physical euphoria|euphoric]] and [[stimulation|stimulating]] effects. Its parent compound, phenmetrazine, was previously marketed as an [[appetite suppressant]] in the 60s and 70s but has since been withdrawn from the market due to concerns of abuse and addiction.

Below is a table showing 3-FPM's ~~affinity~~ (EC50) ~~for~~ [[dopamine]] (~~DAT~~), [[serotonin]] (~~SERT~~) and [[noradrenaline]] (~~NET~~) ~~transporters as well as the values of some other stimulants that are more common~~:

Below is a table showing 3-FPM's potency for inducing release (EC50) of [[dopamine]] (DA), [[serotonin]] (5-HT) and [[noradrenaline]] (NE) in comparison to phenmetrazine:

{|

|-

Line 23:

|-

| '''Compounds >'''<br>'''Monoamine transporters V''' || [[PAL-593]] || [[Phenmetrazine~~]] || [[D-Methylphenidate]] || [[D-Amphetamine~~]]

| '''Compounds >'''<br>'''Monoamine transporters V''' || [[PAL-593]] || [[Phenmetrazine]]

|-

| [[dopamine|~~DAT~~]] || 43 || ~~131 || 41 || 24.8~~

| [[dopamine|DA Release]] || 43 || 87

|-

| [[serotonin|~~SERT~~]] || 2558 || ~~7765 || >1000 || n/a~~

| [[serotonin|5-HT Release]] || 2558 || 3246

|-

| [[noradrenaline|~~NET~~]] || 30 || ~~50 || 345.1 || 7.1~~

| [[noradrenaline|NE Release]] || 30 || 38

|}

|| <ref>https://www.google.com/patents/US20130203752</ref>

|}

Despite being able to compare these values directly, the prediction of possible effects from simply viewing the affinity values of a compound is not very accurate; however, they can be used to hypothesize about 3-FPM's mechanism of action in vivo.

==Subjective effects==

@@ Line 14: / Line 14: @@
 ==Pharmacology==
--FPM is a sympathomimetic drug which has classical [[stimulant]] effects when consumed. Its mechanism of action appears to function by acting as a [[releasing agent]] for [[dopamine]], [[serotonin]], and [[norepinephrine]], increasing their concentrations in the synaptic clefts of neurons in the brain. This accumulation of [[neurotransmitters]] results in the experience of [[physical euphoria|euphoric]] and [[stimulation|stimulating]] effects. Notably, it has a higher affinity for all three [[monoamine]] transporters when compared to [[methylphenidate]]. Its parent compound, phenmetrazine, was previously marketed as an [[appetite suppressant]] in the 60s and 70s but has since been withdrawn from the market due to concerns of abuse and addiction.
+-FPM is a sympathomimetic drug which has classical [[stimulant]] effects when consumed. Its mechanism of action appears to function by acting as a [[releasing agent]] for [[dopamine]] and [[norepinephrine]], increasing their concentrations in the synaptic clefts of neurons in the brain. This accumulation of [[neurotransmitters]] results in the experience of [[physical euphoria|euphoric]] and [[stimulation|stimulating]] effects. Its parent compound, phenmetrazine, was previously marketed as an [[appetite suppressant]] in the 60s and 70s but has since been withdrawn from the market due to concerns of abuse and addiction.
-Below is a table showing 3-FPM's affinity (EC50) for [[dopamine]] (DAT), [[serotonin]] (SERT) and [[noradrenaline]] (NET) transporters as well as the values of some other stimulants that are more common:
+Below is a table showing 3-FPM's potency for inducing release (EC50) of [[dopamine]] (DA), [[serotonin]] (5-HT) and [[noradrenaline]] (NE) in comparison to phenmetrazine:
 {|
 |-
@@ Line 23: / Line 23: @@
 |-
 |-
-| '''Compounds >'''<br>'''Monoamine transporters V''' || [[PAL-593]] || [[Phenmetrazine]] || [[D-Methylphenidate]] || [[D-Amphetamine]]
+| '''Compounds >'''<br>'''Monoamine transporters V''' || [[PAL-593]] || [[Phenmetrazine]]
 |-
-| [[dopamine|DAT]] || 43 || 131 || 41 || 24.8
+| [[dopamine|DA Release]] || 43 || 87
 |-
-| [[serotonin|SERT]] || 2558 || 7765 || >1000 || n/a
+| [[serotonin|5-HT Release]] || 2558 || 3246
 |-
-| [[noradrenaline|NET]] || 30 || 50 || 345.1 || 7.1
+| [[noradrenaline|NE Release]] || 30 || 38
 |}
   || <ref>https://www.google.com/patents/US20130203752</ref>
 |}
-Despite being able to compare these values directly, the prediction of possible effects from simply viewing the affinity values of a compound is not very accurate; however, they can be used to hypothesize about 3-FPM's mechanism of action in vivo.
 ==Subjective effects==